REG-Bioventix Plc: Siemens Launches New Troponin Test <Origin Href="QuoteRef">BVXP.L</Origin>

BioventixAnnouncement

10/05/2017 09:00

Bioventix plc
(“Bioventix” or “the Company”)

Siemens Launches New Troponin Test

The Board has become aware of the launch of a new test by Siemens for
troponin, a key biomarker used in heart attack diagnostics.  This launch is
significant for Bioventix as the test uses antibodies created by Bioventix and
accordingly the Company will receive product royalties based on Siemens
activities in this area.  There is more detailed information on the Siemens
web-site:

http://www.siemens.com/press/en/pressrelease/?press=/en/pressrelease/2017/healthineers/pr2017040269hcen.htm&content[]=HC

For further information please contact:

 Bioventix plc Peter Harrison                         Chief Executive Officer              Tel: 01252 728 001  
                                                                                                               
 finnCap Ltd Geoff Nash/Simon Hicks Stephen Norcross  Corporate Finance Corporate Broking  Tel: 020 7220 0500  

About Bioventix plc:

Bioventix (www.bioventix.com) specialises in the development and commercial
supply of high-affinity monoclonal antibodies with a primary focus on their
application in clinical diagnostics, such as in automated immunoassays used in
blood testing. The antibodies created at Bioventix are generated in sheep and
are of particular benefit where the target is present at low concentration and
where conventional monoclonal or polyclonal antibodies have failed to produce
a suitable reagent. Bioventix currently offers a portfolio of antibodies to
customers for both commercial use and R&D purposes, for the diagnosis or
monitoring of a broad range of conditions, including heart disease, cancer,
fertility, thyroid function and drug abuse. Bioventix currently supplies
antibody products and services to the majority of multinational clinical
diagnostics companies. Bioventix is based in Farnham, UK and its shares are
traded on AIM under the symbol BVXP.

The information communicated in this announcement contains inside information
for the purposes of Article 7 of the Market Abuse Regulation (EU) No.
596/2014.



Copyright (c) 2017 PR Newswire Association,LLC. All Rights Reserved